View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

CRISPR Therapeutics to Present at the Bank of America Securities Healt...

CRISPR Therapeutics to Present at the Bank of America Securities Health Care Conference ZUG, Switzerland and BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the Bank of America Securities Health Care Conference on Wednesday, May 15, 2024, at 12:20 p.m. ET. A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Comp...

 PRESS RELEASE

Stryker declares a $0.80 per share quarterly dividend

Stryker declares a $0.80 per share quarterly dividend Portage, Michigan, May 09, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.80 per share payable July 31, 2024 to shareholders of record at the close of business on June 28, 2024, representing an increase of 6.7% versus the prior year and unchanged from the previous quarter.  About Stryker Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and s...

 PRESS RELEASE

RxSight, Inc. Announces Pricing of Public Offering of Common Stock

RxSight, Inc. Announces Pricing of Public Offering of Common Stock ALISO VIEJO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, announced today that it has priced its underwritten public offering. RxSight expects to sell 1,785,714 shares of its common stock at a price to the public of $56.00 per share. RxSight has granted the underwriters a 30-day option to purchase up to an additional 267,857 shares of its common stock at the public...

 PRESS RELEASE

HCI Group Reports First Quarter 2024 Results

HCI Group Reports First Quarter 2024 Results First Quarter Pre-Tax Income of $77.4 millionFirst Quarter Diluted EPS of $3.81First Quarter Gross Loss Ratio of 31.1% TAMPA, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- HCI Group, Inc. (NYSE:HCI), a holding company with operations in homeowners insurance, information technology services, real estate, and reinsurance, reported pre-tax income of $77.4 million and net income of $57.0 million, or $3.81 diluted earnings per share, in the first quarter of 2024, compared with net income of $17.8 million, or $1.54 diluted earnings per share, in the first ...

 PRESS RELEASE

Royal Gold Reports Strong Start to 2024 with Significant Liquidity Inc...

DENVER--(BUSINESS WIRE)-- Royal Gold, Inc. (NASDAQ: RGLD) (together with its subsidiaries, “Royal Gold,” the “Company,” “we,” “us,” or “our”) reports net income of $47.2 million, or $0.72 per share, for the quarter ended March 31, 2024, ("first quarter") on revenue of $148.9 million and operating cash flow of $138.3 million. Adjusted net income1 was $59.8 million, or $0.91 per share. First Quarter 2024 Highlights: Solid financial results with revenue of $148.9 million, operating cash flow of $138.3 million and earnings of $47.2 million Revenue split: 75% gold, 13% silver, 9% copper ...

 PRESS RELEASE

RxSight, Inc. Announces Proposed Public Offering of Common Stock

RxSight, Inc. Announces Proposed Public Offering of Common Stock ALISO VIEJO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., (Nasdaq: RXST), an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, announced today that it intends to offer and sell, subject to market and other conditions, $100 million of shares of its common stock in an underwritten public offering. In addition, RxSight expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered...

 PRESS RELEASE

CRISPR Therapeutics Provides Business Update and Reports First Quarter...

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results -More than 25 authorized treatment centers (ATCs) activated globally for CASGEVY™ and multiple patients have already had cells collected- -Clinical trials ongoing for next generation CAR T product candidates, CTX112™ and CTX131™ targeting CD19 and CD70 respectively, across multiple indications- -Clinical trials ongoing for in vivo gene editing product candidates, CTX310™ and CTX320™ targeting ANGPTL3 and Lp(a), respectively- -Expands pipeline with new preclinical programs utilizing lipid nanopar...

Pierre FerraguÊ
  • Pierre FerraguÊ
 PRESS RELEASE

CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces N...

CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo Gene Editing Approach - ASGCT presentation demonstrates lipid nanoparticle (LNP) mediated delivery to the eye in the context of editing of the myocilin (MYOC) gene as a potential treatment for glaucoma - - Expands pipeline with new pre-clinical programs utilizing LNP mediated delivery to the liver for refractory hypertension targeting angiotensinogen (AGT) and acute hepatic porphyria (AHP) targeting 5’-aminolevulinate synthase 1 (ALAS1) - - CTX340™, targeting AGT in the liver, achieved dura...

 PRESS RELEASE

ALX Oncology Appoints Allison Dillon as Chief Business Officer

ALX Oncology Appoints Allison Dillon as Chief Business Officer SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced the appointment of Allison Dillon, Ph.D., as Chief Business Officer (“CBO”). “We are excited to welcome Allison to our leadership team in the midst of this promising growth period for our Company,” said Jason Lettmann, Chief Executive Officer of ALX Oncology. “For over 15 yea...

Soomit Datta
  • Soomit Datta

KSPI US (Buy, TP: $175, +45%) # INITIATION OF COVERAGE # Kaspi (Buy)...

Kaspi is a Super App the likes of which we haven’t really seen develop outside of China. Dominant in Payments, roots in lending and with group growth currently driven by triple digit top-line in the leading local E-Commerce platform. Obvious comparisons in our coverage are with MercadoLibre (Buy), which we continue to be positive on and which we benchmark Kaspi against in this note.

Wedbush Research
  • Wedbush Research
TPX TEMPUR SEALY INTERNATIONAL INC
GEO GEO GROUP INC. (THE)
2454 MEDIATEK INC.
MTB M&T BANK CORPORATION
STZ CONSTELLATION BRANDS INC. CLASS A
UBI UBISOFT ENTERTAINMENT SA
QRVO QORVO INC.
DPZ DOMINO'S PIZZA INC.
WDC WESTERN DIGITAL CORPORATION
VRNS VARONIS SYSTEMS INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
QCOM QUALCOMM INC
PSTG PURE STORAGE INC. CLASS A
PEGA PEGASYSTEMS INC.
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
NCMI NATIONAL CINEMEDIA INC.
MU MICRON TECHNOLOGY INC.
MGPI MGP INGREDIENTS INC.
MFA MFA FINANCIAL INC.
INTC INTEL CORPORATION
IMAX IMAX CORPORATION
GOOGL ALPHABET INC. CLASS A
GERN GERON CORP.
FIS FIDELITY NATIONAL INFORMATION SERVICES INC.
FHN FIRST HORIZON CORPORATION
EPAM EPAM SYSTEMS INC.
DECK DECKERS OUTDOOR CORPORATION
CNK CINEMARK HOLDINGS INC.
CHKP CHECK POINT SOFTWARE TECHNOLOGIES LTD.
AMC AMC ENTERTAINMENT HOLDINGS INC. CLASS A
OSTK OVERSTOCK.COM INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
HPE HEWLETT PACKARD ENTERPRISE CO.
FCNCA FIRST CITIZENS BANCSHARES INC. CLASS A
CELH CELSIUS HOLDINGS INC.
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
AVGO BROADCOM INC.
TENB TENABLE HOLDINGS
GOSS GOSSAMER BIO
DELL DELL TECHNOLOGIES INC CLASS C
STOK STOKE THERAPEUTICS
SMCI SUPER MICRO COMPUTER
ORIC INC.
TVTX ORIC PHARMACEUTICALS
PLTR TRAVERE THERAPEUTICS INC
DAWN PALANTIR TECHNOLOGIES
TDUP DAY ONE BIOPHARMACEUTICALS INC
MRVL THREDUP INC.
STX MARVELL TECHNOLOGY INC
HOWL SEAGATE TECHNOLOGY HLDGS PLC
PAY WEREWOLF THERAPEUTICS INC
GFS PAYMENTUS HLDGS INC
BROS GLOBALFOUNDRIES INC
DUTCH BROS INC

Arcos Dorados Holdings Inc.: Update to credit analysis after the chang...

Our credit view of this issuer reflects its good liquidity and its leading market position in Latin America, offset by its foreign exchange rate risk.

 PRESS RELEASE

RxSight, Inc. Reports First Quarter 2024 Financial Results

RxSight, Inc. Reports First Quarter 2024 Financial Results ALISO VIEJO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended March 31, 2024. Key Quarterly Highlights Reported first quarter 2024 revenue of $29.5 million, an increase of 69% compared to the first quarter of 2023, reflecting: The sale of 20,218 Light Adjustable Lenses (LAL®/LAL+™), representing a 92% ...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch